Meeting
2017 ASCO Annual Meeting
Tumor shrinkage and increased overall survival are associated with improved albumin, neutrophil lymphocyte ratio (NLR) and decreased durvalumab clearance in NSCLC and UC patients receiving durvalumab.
Authors
Thomas Powles
Barts Cancer Institute, London, United Kingdom
Thomas Powles , Chaoyu Jin , Yanan Zheng , Paul Baverel , Rajesh Narwal , Pralay Mukhopadhyay , Xiaoping Jin , Phillip A. Dennis , Ashok Kumar Gupta , Yong Ben , Tony W. Ho , Lorin Roskos
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research,Immunotherapy
Sub Track
Biomarkers and Correlative Studies from Immunotherapy Trials
Citation
J Clin Oncol 35, 2017 (suppl; abstr 3035)
DOI
10.1200/JCO.2017.35.15_suppl.3035
Abstract #
3035
Poster Bd #
130
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Tumor kinetic modeling and identification of predictive factors for tumor response to durvalumab in patients with non-small cell lung cancer (NSCLC).
First Author: Yanan Zheng
Poster
2021 ASCO Annual Meeting
Randomized phase III Trial of MEDI4736 (durvalumab) as concurrent and consolidative therapy or consolidative therapy alone for unresectable stage 3 NSCLC: A trial of the ECOG-ACRIN Cancer Research Group (EA5181).
First Author: John M. Varlotto
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
The prognostic significance of PDL1 expression in locally advanced non-small-cell lung cancer (LA-NSCLC) treated with definitive intent.
First Author: Devarati Mitra
Poster
2016 ASCO Annual Meeting
Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naïve patients with advanced non‒small-cell lung cancer.
First Author: Scott Joseph Antonia